Oncolytics Biotech (NASDAQ: ONCY) has announced that data continues to demonstrate a favorable safety profile for intravenously administered pelareorep across multiple gastrointestinal (GI) tumors, and in combination with multiple treatments.
According to Oncolytics, pelareorep has been administered in more than 1,200 patients, including 300+ patients with various GI tumors. It has been evaluated in combination with new treatment regimens like modified FOLFIRINOX in metastatic pancreatic cancer and in other tumor types, including colorectal cancer and anal cancer.
Jared Kelly, CEO of Oncolytics, commented, “With over 1,200 patients dosed and a consistent safety profile, pelareorep represents one of the most de-risked immunotherapies that is not already approved as a treatment option in GI tumors. As we move forward to registration-enabled studies, we are confident the safety data will be a positive characteristic for regulators and potential partners.”
